Rosiglitazone Effect on Radioiodine Uptake in a Case of Dedifferentiated Thyroid Carcinoma
Thyroid and Parathyroid Diseases: A Case-Based Guide, Springer International Publishing Ag, ss.297-303, 2018
- Yayın Türü: Kitapta Bölüm / Araştırma Kitabı
- Basım Tarihi: 2018
- Doi Numarası: 10.1007/978-3-319-78476-2_47
- Yayınevi: Springer International Publishing Ag
- Sayfa Sayıları: ss.297-303
- Anahtar Kelimeler: Aggressive Tumor Type, Differentiated Thyroid Cancer (DTC), Radioiodine (RAI), RAI Uptake, Rosiglitazone (RZ)
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Differentiated thyroid cancer may lose its differential characteristics and transform to a less-differentiated form that does not concentrate radioiodine. These tumors represent an aggressive tumor type and may necessitate alternative therapies. Various attempts have been made to augment iodine uptake and to redifferentiate tumors in order to regain benefit from radioiodine therapy. Thiazolidinediones, such as rosiglitazone, act by binding to peroxisome proliferator-activated receptors (PPARs) and have also shown promise in the redifferentiation treatment of dedifferentiated thyroid carcinomas as antiproliferative and apoptosis-inducing agents. In this section, the effect of rosiglitazone is discussed in a case with dedifferentiated thyroid cancer.